A Study of Lebrikizumab in Patients with Persistent Moderate to Severe Atopic Dermatitis The primary objective of this study is to evaluate the efficacy and safety of lebrikizumab used as adjunctive therapy with topical corticosteroid (TCS) compared with TCS alone in patients with persis...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Clinical trial to test the efficacy and the safety of MPDL3280A compared with Docetaxel in patients with non-small cell lung cancer. Ensayo clínico para probar la eficacia y la seguridad de MPDL3280A en comparación con docetaxel en pacientes con cáncer de pulmón de células no microcíticas ? To estimate the efficacy of MPDL3280A compared with docetaxel as measured by OS ?To evaluate the safety and tolerability of MPDL3280A compared with docetaxel ?Estimar la eficacia de MPDL3280A...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo que compara la eficacia y seguridad de valganciclovir administrado durante 100 días frente a valganciclovir administrado durante 200 días en la prevención de enfermedad por citomegalovirus en pacientes receptores de alto riesgo de aloinjerto renal 1. Comparar la eficacia de valganciclovir profiláctico (900 mg una vez al día) administrado durante 100 días frente a valganciclovir profiláctico (900 mg una vez al día) administrado durante 200 días,...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 µg Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg To compare the efficacy and safety of 360 µg induction dosing of Pegasys for 12 weeks followed by a 180 µg maintenance dose of Pegasys for 36 weeks in combination with Copegus for 48 weeks with the ef...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS) The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality in stable CHD patients, with a documented recent ACS.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, controlled, open-label, multi-center, parallel group study to demonstrate efficacy and safety of RO0503821 when administered with pre-filled syringes for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis To demonstrate that RO0503821 administered in pre-filled syringes maintains hemoglobin concentrations in dialysis patients on prior intravenous or subcutaneous Epoetin maintenance treatment of chronic...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Randomized, double-blind, placebo-controlled add-on trial of the safety and efficacy of RO4917838 in outpatients on select atypical antipsychotics with prominent negative or disorganized thought symptoms To evaluate the effect of RO4917838 compared to placebo on negative symptoms based on the mean change from baseline in Positive and Negative Syndrome Scale (PANSS) negative factor score after 8 weeks ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study of Gantenerumab in Patients with Mild Alzheimer Disease Double-blind treatment period (Part 1): To evaluate the efficacy of gantenerumab administered to patients by SC injection over 100 weeks vs. placebo on measures of cognition (ADASCog) and function (A...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase II study of orally administered RO4929097, a gamma-secretase inhibitor, as a single agent in patients with recurrent or refractory Non-Small Cell Lung Cancer (NSCLC) To evaluate the effect of RO4929097 on tumor blood flow and tumor metabolic activity.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase II study to assess vismodegib in the treatment of idiopathic pulmonary fibrosis - Change in pulmonary function (FVC% predicted) from baseline to week 52

• Pays Aucun
• Organes Aucun
• Spécialités Aucune